Prenetics’ IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements
Rhea-AI Summary
Prenetics' IM8 has announced a collaboration with Mayo Clinic to develop a new line of premium supplements, focusing on nutrition, cellular rejuvenation, protein, collagen, and overall wellness. The partnership, announced after IM8's official launch on November 18th on IM8health.com, combines IM8's innovation with Mayo Clinic's medical expertise to create evidence-based, clinically researched supplements.
The collaboration includes contributions from Dr. Dawn Mussallem, a Mayo Clinic integrative oncologist who serves on IM8's Scientific Advisory Board. Mayo Clinic maintains a financial interest in the referenced technology and will direct any revenue toward its not-for-profit mission in patient care, education, and research.
Positive
- Strategic partnership with prestigious Mayo Clinic enhances product credibility
- Access to Mayo Clinic's medical expertise for product development
- Addition of Mayo Clinic integrative oncologist to Scientific Advisory Board
Negative
- None.
News Market Reaction
On the day this news was published, PRE declined 1.86%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Collaboration to Focus on Nutrition, Cellular Rejuvenation, Protein, Collagen and Overall Wellness
IM8, a New Premium Supplements Brand, Launched Officially on November 18th on IM8health.com
CHARLOTTE, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Prenetics’ (NASDAQ:PRE) IM8, a premium supplements brand focused on science-driven health solutions, is excited to announce a collaboration through a know-how agreement with Mayo Clinic to develop a new generation of premium supplements. This collaboration aims to advance health and longevity through the fusion of IM8’s cutting-edge innovation and Mayo Clinic’s medical expertise.
The collaboration will focus on creating evidence-based, clinically researched supplements designed to address key health priorities such as optimal nutrition, cellular rejuvenation, protein support, collagen health, muscle recovery, and overall well-being. The work seeks to ensure that every product developed meets the highest standards of science and efficacy, empowering individuals to take charge of their health with confidence.
“This collaboration with Mayo Clinic marks a significant milestone for IM8,” said Danny Yeung, CEO of Prenetics. “Together, we aim to redefine health and wellness by creating premium supplements that merge scientific rigor with tangible health benefits. Our work has already started, and the initial research is yielding highly promising insights that inspire confidence in the potential of this initiative.”
The collaboration includes contributions from Dawn Mussallem, M.D., a Mayo Clinic integrative oncologist and a member of IM8’s Scientific Advisory Board. Dr. Mussallem’s unique medical insights will guide the development of supplements that address key health priorities with precision and scientific rigor.
Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.
ABOUT PRENETICS
Prenetics (NASDAQ:PRE), a leading health sciences company, is dedicated to advancing consumer and clinical health. Our consumer initiative is led by IM8, a new health and wellness brand, and Europa, one of the largest sports distribution companies in the USA. Our clinical division is led by Insighta, our
Investor Relations Contact:
Angela Cheung
Investor Relations / Corporate Finance
Prenetics Global Limited
angela.hm.cheung@prenetics.com
Shannon Devine
MZ North America
Main: 203-741-8811
shannon.devine@mzgroup.us
FAQ
What is the focus of Prenetics' IM8 and Mayo Clinic collaboration?
When did Prenetics (PRE) launch the IM8 supplement brand?
How will Mayo Clinic benefit from the collaboration with Prenetics' IM8?
Who is involved in the scientific development of IM8's supplements?
